Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Friday 05 February, 2010

Lipoxen PLC

Trading and Programme Update

RNS Number : 7252G
Lipoxen PLC
05 February 2010


5 February 2010



Lipoxen plc

('Lipoxen' or 'the Company')


Trading and Programme Update



Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, provides a trading update for the period ended 31 December 2009, prior to announcing its final results in April 2010.


Lipoxen reports that, due to a delay in the Phase II clinical trials for long-acting EPO and Insulin, the potential licensing revenues accompanying these candidates did not materialize in H2 2009 as originally expected; as a consequence the Company did not meet its revenue expectations for the second half of 2009.


While operating costs remained tightly controlled, the quantum of cost reduction was not enough to offset the level of revenue shortfall. As a result, the Company's net cash position of £1.02 million at 31 December 2009 was below management expectations. To this end Lipoxen will continue to review its cash requirements whilst pursuing revenue from licensing deals and other funding options.

Importantly Lipoxen has implemented a laboratory restructuring to move the Company's focus from a scientific research-driven and intellectual property company to one focused on maximising near term commercial opportunities in FY2010 for its platform technologies and lead projects. This has involved some staff changes, including the departure of Dr Peter Laing (former Chief Operating Officer of the Company's operating subsidiary, Lipoxen Technologies Limited). As announced in September 2009, the Company appointed Dr David Moss as Director of Projects to deliver on the Company's commercial objectives.


Lead Projects Update




The Serum Institute of India ("Serum Institute"), Lipoxen's partner responsible for conducting its Phase II trial ErepoXen in India, has agreed to accelerate the product candidate towards marketability by expanding the planned trial into a fully integrated Phase II US FDA compliant trial. This has necessitated the engagement of a specialised Contract Research Organisation to carry out the multi-centre trial and new regulatory permissions. Although the project experienced an interim delay as a result, the required documentation has now been submitted to the Indian Regulatory Authority (DCGI) and Lipoxen expects to announce formal dosing of the first patient in Q1 of 2010.


The additional cost of the expanded Indian ErepoXen Phase II trial will be met by the Serum Institute. This however has culminated in the Serum Institute taking the decision that it is no longer in a position to fund the earlier stage ErepoXen Phase I trial in Canada, as previously agreed. As a result, the Canadian trial is on hold until Lipoxen concludes an alternative funding route.




FDS Pharma ("FDS"), Lipoxen's Russian counterparty responsible for the Company's Phase II Insulin trial of SuliXen in Russia, was unable to commence the trial at the end of 2009. In consultation with FDS, the Company is resetting the timelines for this trial with a view to initiating it in the first half of 2010.


Initial results from the Barbara Davis Institute study of SuliXen for Type 1 diabetes have indicated that this study will be extended through Q1 of 2010. While the Company initially expected to report on this study in Q4 of 2009, following the extension of the study, Lipoxen now anticipates being in a position to report in Q2 this year.



H1N1 Influenza Vaccine


As announced at the end of September 2009, Lipoxen has been appointed the lead member of the grant consortium to develop a novel H1N1 influenza vaccine. This programme is being funded by the UK Technology Strategy Board. While still at an early preclinical stage, this programme is progressing well and, when the latter stages of the programme have been successfully attained, Lipoxen expects to apply for further funding to move the vaccine candidate into the clinic within the next 12 months.


Baxter Healthcare


Lipoxen's Factor VIII project, which is partnered with Baxter, is progressing well and, as expected, the Company anticipates lead Product Candidate declaration in the first half of this year.  Baxter is now the Company's third largest shareholder and sees the potential for broadening the collaboration this year.


HIV and Malaria Vaccine


The Company's HIV project, partnered with the world's leading HIV vaccine organization, International AIDS Vaccine Initiative, remains on track to report in Q1 of 2010 and Lipoxen's novel malaria project partnered with PATH Malaria Vaccine Initiative and the US NIH, is expected to report in the same time frame.


siRNA Delivery Project


Lipoxen's agreement, announced in June 2009, for its siRNAblate technology to evaluate the effectiveness of combining its partner's (currently undisclosed) proprietary siRNA with Lipoxen's platform technology, is progressing well and the Company will provide a further update in the near future. 


Other Projects


The Company's collaboration with Pharmasynthez ZAO, announced in November 2009, to apply Lipoxen's ImuXen and PolyXen proprietary technologies to a broad range of six drug and vaccine candidates, is progressing well. This project will provide human proof of concept data on Lipoxen's vaccine platform technology as early as the end of this year.


Commenting on the trading update, M. Scott Maguire, CEO of Lipoxen, said: "We are delighted that the Serum Institute has decided to extend the Phase II ErepoXen trial in India to a fully compliant FDA trial. While incurring an initial delay, we are very pleased that the product will be accelerated to market.


"Following the recent restructuring, Lipoxen is better able to focus on delivering the near term commercial opportunities for its promising platform technologies. We therefore are confident of delivering value enhancing newsflow over the course of the next few months."


- Ends -


For further information please contact:


Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating, Claes Spång

Noble & Company

+44 (0)20 7763 2200

James Bromhead, Sam Reynolds   

Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Catherine Breen


Notes for Editors


About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:


1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA


Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 


Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for Factor VIII


The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, Amgen and Genzyme.  Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009.


Lipoxen, which was founded in 1997, now trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website:



This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t